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Objectives: The aim of the present research was to syn-
thesise several novel fluorinated quinazolineesulphona-
mide derivatives and to evaluate their in vitro cytotoxic
activity.
Methods: Eight compounds were synthesised. The com-
pounds’ anticancer activities were determined through
the [3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyltetrazolium
bromide] (MTT) assay using a three-cell-line panel con-
sisting of National Cancer Institute (NCI) lung cancer
cells, Michigan Cancer Foundation-7 (MCF-7) breast
cancer cells, and Human Embryonic Kidney-293 (HEK-
293) normal kidney cell. The values of C log P correla-
tions were determined to interpret the results.
Results: One compound exhibited significant anticancer
activity with low toxicity compared with the methotrexate
as the reference drug. The biological screening showed
good to moderate anticancer activity for the title com-
pounds compared with the reference drug. The reference
drug exhibited an IC50 value of 2.4 mM, whereas com-
pound 9, which was identified as the most active com-
pound, exhibited an IC50 value of 2.51 mM on the NCI
cell line. The other compounds showed IC50 values that
ranged from 2.89 to 46.34 mM on the three cell lines. The
newly synthesized compounds had lower toxicity on the
normal cell line than did methotrexate.
Conclusions: The newly synthesized compounds may
provide a valuable template for future design andhis is an open access article under the CC BY-NC-ND license
16/j.jtumed.2015.02.007
M.F. Zayed et al.334optimization to produce analogues that act as more
active anticancer agents.
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NC-ND license (http://creativecommons.org/licenses/by-nc-
nd/4.0/).Introduction
Quinazolinones have various biological activities,
including anticonvulsant,1,2 antihistaminic,3 anti-
inflammatory, antibacterial,4 antidiabetic,5 antifungal,6
anticancer,7 anthelmintics8 and antiviral activities.9
Quinazolinone derivatives produce their anticancer
activity through potent inhibition of various enzymes,
such as epidermal growth factor receptor tyrosine kinase,
dihydrofolate reductase, folate thymidylate synthase,
tyrosine kinase, aldose reductase, cyclic GMP
phosphodiesterase and DNA repairing enzymes.7
Quinazolinone derivatives have therefore been widely
used in the production of anticancer drugs.7 In contrast,
sulphonamides have various biological activities, and
some of them are widely used in therapy as substantial
anticancer agents.10,11 Sulphonamides act as anticancer
agents through a variety of mechanisms, such as cell cycle
perturbation in the G1 phase, disruption of microtubule
assembly, functional suppression of the transcriptional
activator NF-Y12,13 and inhibition of the carbonic
anhydrase (CA) enzyme.14 In our previous studies,15 we
reported that some derivatives of 6,8-diiodo-2-phenyl-3-
substituted-quinazolin-4(3H)-ones, such as compound
(A), exhibit good cytotoxic activity (Figure 1). These
derivatives are hybrid molecules that included 6,8-diiodo
quinazolinone as a fixed moiety with different L-amino
acids. Iodine atoms at positions 6 and 8 of the quinazoli-
none moiety have larger atomic size, atomic radius, atomic
covalent bond and van der Waals radius than other halo-
gens, such as fluorine.18 The large size of iodine atoms may
negatively affect the drug receptor binding process by
changing the desolvation energy, which plays an
important role in ligandereceptor interactions.19,20
Furthermore, fluorine improved the lipophilicity,
absorption and bioavailability of many well-established
anticancer drugs16 such as lapatinib, gefitinib and
caneratinib.17,21 We therefore decided to synthesise some
novel fluorinated quinazolinones with the same structure
as our previously reported compounds but with an iodine
atom instead of a fluorine atom at position 6 of the
quinazolinone moiety. Figure 1 shows the structural
similarities between the previously reported anticancer
quinazolinones (A, B), Thymitaq and the newly
synthesized derivatives.22,23 The present study is thus a
continuation of our attempt to identify novel, safe and
effective anticancer agents.Materials and Methods
Synthesis
The strategy used to synthesise the compounds is shown
in Scheme 1. It comprises two simple reactions, namely
acetylation followed by ring closure of 2-amino-5-
flurobenzoic acid (1). This compound was refluxed with
acetic anhydride for 1 h to afford a quantitative yield of 6-
fluoro-2-methyl-4H-benzo[d][1,3]oxazin-4-one (2). The
second reaction is the nucleophilic displacement of the
oxygen of benzoxazinone with the nitrogen of the amino
group upon treatment with sulphonamides, which
was achieved by refluxing compound (2) with the appro-
priate sulphonamide under dry conditions for 6 h and
gave sulphonamide derivatives of 6-fluoro-2-methyl-qui-
nazolinone (4e11) in variable yields ranging from 60 to
79%.Chemistry
The compounds were analysed at the Analytical Centre,
College of Science, Cairo University, Egypt. The melting
points were measured using a Griffin melting point appa-
ratus (Griffin) and are uncorrected. The Infrared spectra
were recorded as KBr discs on a Nicolet IR 200 (Thermo
Fisher Scientific). The 1HNMR spectra were run using TMS
as the internal standard (SigmaeAldrich) on a Varian
Mercury VXr-300 NMR instrument (Varian). The mass
spectra were measured on a JEOL-SX-102 instrument
through electron impact ionization. Elemental analyses (C,
H, and N) were performed using a Perkin-Elmer 240C ana-
lyser (Perkin-Elmer). All of the values were within 0.4% of
the theoretical values. All of the chemicals were purchased
from SigmaeAldrich.Experimental
6-Fluoro-2-methyl-4H-benzo[d][1,3]oxazin-4-one (2)
Compound 2 was prepared by refluxing 2-amino-5-
fluorobenzoic acid (1, 1.55 g, 0.01 mol) with an appropriate
amount of acetic anhydride for 1 h. The residue obtained was
evaporated to complete dryness, allowed to cool, washed
several times with petroleum ether, collected, filtered and
dried without moisture.
Yield 79%, mp: 87e89 C; 1H NMR (DMSO-d6): d 1.41
(s, 3H, CH3), 7.31e8.24 (m, 3H, AreH).
13C NMR (DMSO-
d6): d 24.23, 82, 90.5, 118.5, 138.2, 149.6, 150, 154.1, 158.
Anal. Calcd. For C9H6FNO2 (179.04): C, 60.34; H, 3.38; N,
7.82. Found C, 60.12; H, 3.61; N, 7.64. MS (EI) m/z 180.04
[M þ 1].General method for preparation of test compounds (4e11)
Compounds 4e11 were prepared by mixing 1.79 g
(0.01 mol) of compound (2) with 0.01 mol of sulphonamide
derivatives in 100 ml of dry pyridine, refluxing for 6 h,
cooling, treating with a small amount of 10% hydrochloric
acid and pouring onto crushed ice. The crystals obtained
were collected by filtration and re-crystallised from ethanol
or glacial acetic acid.
Figure 1: Structural similarities and pharmacophoric features of the reported and designed quinazolinones (4e14) as cytotoxic agents.
Synthesis and screening of new anticancer agents 3354-(6-Fluoro-2-methyl-4-oxoquinazolin-3(4H)-yl)
benzensulphonamide (4)
Yield 68%, mp: 152e154 C; 1H NMR (DMSO-d6):
d 2.46 (s, 3H, CH3), 5.2 (s, 2H, NH2), 7.02e7.94 (m, 7H, Are
H). Anal. Calcd. for C15H12FN3O3S (333.06): C, 54.05; H,
3.63; N, 12.61. Found C, 53.91; H, 3.82; N, 12.49. MS (EI)
m/z 334.06 [M þ 1].4) R = Hydrogen 
5) R = Pyridin-2-yl
6) R = 3,4-dimethylisoxazol-5-yl
7) R = Thiazole-2-yl
8) R = 5-methylisoxazol-3-yl
9) R = 4,6-dimethlpyrimidin-2-yl
10) R = 4-methylpyrimidin-2-yl
11) R = Diaminomethylene
Scheme 1: Synthesis of th4-(6-Fluoro-2-methyl-4-oxoquinazolin-3(4H)-yl)-N-(pyridin-2-yl)
benzensulphonamide (5)
Yield 65%, mp: 161e163 C; 1H NMR (DMSO-d6):
d 2.12 (s, 3H, CH3), 7.02e8.25 (m, 11H, AreH), 8.41 (s, 1H,
NH). Anal. Calcd. For C20H15FN4O3S (410.08): C, 58.53; H,
3.68; N, 13.65. Found C, 58.62; H, 3.71; N, 13.83. MS (EI)
m/z 411.08 [M þ 1].e target compounds.
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dimethylisoxazol-5-yl)benzensulphonamide (6)
Yield 62%, mp: 156e158 C; 1H NMR (DMSO-d6):
d 2.27 (s, 6H, 2CH3), 2.51 (s, 3H, CH3), 7.13e8.27 (m, 7H,
AreH), 8.41 (s, 1H, NH). Anal. Calcd. For C20H17FN4O4S
(428.1): C, 56.07; H, 4.00; N, 13.08. Found C, 56.31; H, 3.87;
N, 12.97. MS (EI) m/z 429.1 [M þ 1].
4-(6-Fluoro-2-methyl-4-oxoquinazolin-3(4H)-yl)-N-(thiazole-2-
yl)benzensulphonamide (7)
Yield 60%, mp: 174e176 C; 1H NMR (DMSO-d6): d
2.45 (s, 3H, CH3), 7.12e8.43 (m, 9H, AreH), 8.61 (s,
1H, NH). Anal. Calcd. For C18H13FN4O3S2 (416.04): C,
51.91; H, 3.15; N, 13.45. Found C, 51.81; H, 3.42; N, 13.25.
MS (EI) m/z 417.04 [M þ 1].
4-(6-Fluoro-2-methyl-4-oxoquinazolin-3(4H)-yl)-N-(5-
methylisoxazol-3-yl)benzensulphonamide (8)
Yield 62%, mp: 164e166 C; 1H NMR (DMSO-d6):
d 2.42 (s, 3H, CH3), 2.76 (s, 3H, CH3), 7.11e8.24 (m, 8H,
AreH), 8.41 (s, 1H, NH). Anal. Calcd. For C19H15FN4O4S
(414.08): C, 55.07; H, 3.65; N, 13.52. Found C, 55.19; H,
3.91; N, 13.44. MS (EI) m/z 415.08 [M þ 1].
4-(6-Fluoror-2-methyl-4-oxoquinazolin-3(4H)-yl)-N-(4,6-
dimethlpyrimidin-2-yl)benzensulphonamide (9)
Yield 65%, mp: 168e170 C; 1H NMR (DMSO-d6):
d 2.31 (s, 3H, CH3), 2.46 (s, 6H, 2CH3), 6.98e8.08 (m, 8H,
AreH), 8.31 (s, 1H, NH). Anal. Calcd. For C21H18FN5O3S
(439.11): C, 57.39; H, 4.13; N, 15.94. Found C, 57.24; H,
4.51; N, 15.78. MS (EI) m/z 440.11 [M þ 1].
4-(6-Fluoro-2-methyl-4-oxoquinazolin-3(4H)-yl)-N-(4-
methylpyrimidin-2-yl)benzensulphonamide (10)
Yield 60%, mp: 163e165 C; 1H NMR (DMSO-d6):
d 2.25 (s, 3H, CH3), 2.64 (s, 3H, CH3), 7.02e8.33 (m, 9H,
AreH), 8.51 (s, 1H, NH). Anal. Calcd. For C20H16FN5O3S
(425.1): C, 56.46; H, 3.79; N, 16.46. Found C, 56.31; H, 3.62;
N, 16.37. MS (EI) m/z 426.1 [M þ 1].
N-(diaminomethylene)-4-(7-fluoro-2-methyl-4-oxoquinazolin-
3(4H)-yl)benzensulphonamide (11)
Yield 60%, mp: 145e147 C; 1H NMR (DMSO-d6):
d 2.31 (s, 3H, CH3), 6.91e8.14 (m, 7H, AreH), 8.29e8.65
(m, 4H, 2NH2). Anal. Calcd. For C16H14FN5O3S (375.08):
C, 51.19; H, 3.76; N, 18.66. Found C, 51.03; H, 3.58; N,
18.81. MS (EI) m/z 376.05 [M þ 1].
Biological screening
The newly synthesized compounds were screened for their
cytotoxic activities using NCI (lung cancer cell line), MCF 7
(breast cancer cell line) and HEK293 (normal kidney cell
line) cells by the MTT (3-(4,5-dimethyl-2-thiazolyl)-2,5-
diphenyltetrazolium bromide) assay.24 The screening
experiments were conducted at the National Cancer
Institute (NCI, Cairo, Egypt) and undertaken with
approval from Taibah University, Al-madinah Al-muna-
warah, Saudi Arabia (approval #3006/434).
The cultures were inspected using an inverted microscope
to determine the degree of viability. The absence of fungal
and bacterial contaminants was confirmed. The cellmonolayer was washed with phosphate buffer saline (PBS)
without calcium and magnesium ions using a volume equiv-
alent to half the volume of culturemedium.ATrypsin/EDTA
mixture was added to the washed cell monolayer using 1 ml
per 25 cm2 of surface area. The flask containing this mixture
was rotated to cover the monolayer with trypsin and then
incubated for 2e4 min. All of the cells were examined using
an inverted microscope to confirm that they were detached
and floated. The cells were suspended in a small volume of
fresh serum containing HEK-293 medium, and 100e200 ml
was removed for cell counting. The required number of cells
were moved to a new labelled flask containing warmedHEK-
293medium and incubated as appropriate for the cell line. All
of the cytotoxicity screening experiments were performed in
96-well plates.Methotrexate was used as a reference standard
for measuring the cytotoxic activity. The test compounds
were prepared using 2% DMSO solution. The IC50 values,
which are the drug concentrations causing a 50% inhibition
of cell proliferation, were calculated.
Cytotoxic assay
Cytotoxic assays were performed according to the re-
ported method.24 First, the cells were incubated at a
concentration of 1  106 cells/ml in culture medium for 3 h
at 37 C and 6.5% CO2. After incubation, the cells were
seeded at a concentration of 5  104 cells/well in 100 ml of
culture medium with different concentrations (0.005e
100 mM/ml) of the reference drug methotrexate and the
synthesized compounds, which were dissolved in 2%
DMSO (dimethylsulphoxide) solution into microplates
(tissue culture grade, 96 wells, flat bottom) and incubated
for 24 h at 37 C and 6.5% CO2. The cell proliferation
process is based on the ability of the mitochondrial
succinate tetrazolium reductase system to convert 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide
(MTT) to a blue-coloured formazan. The test indicates the
survival of the cells after toxic exposure. Then, 10 ml of the
MTT labelling mixture was added, and the mixture was
incubated for 4 h at the same conditions. Each experiment
was performed three times. Then, 100 ml of the solubilization
solution was added into each well, and the mixtures were
incubated overnight. The absorbance of the samples was
measured by spectrophotometry using a microplate (ELISA)
reader. The formazan wavelength is between 550 and 600 nm
according to the filters used for the ELISA reader. The
reference wavelength should be more than 650 nm. The value
of IC50 was then calculated as the drug concentration that
caused a 50% inhibition of cell proliferation. The HEK 293
cell line was used to determine the cytotoxic effects of the
synthesised compound on the non-cancerous cells.
Statistical analysis
The data obtained are expressed as the means  SE. The
statistical significance of the data was evaluated by one-way
analysis of variance (ANOVA) followed by Tukey’s test as a
post ANOVA multiple-comparison test of the IC50 of the all
of the compounds against methotrexate (Sigma Stat, version
3; SPSS Inc.). A P value <0.05 was considered statistically
significant.
Table 2: C log P values of the target compounds.
Compound No. R C log P value
4 H 1.85604
5
N
2.98086
6
N O
2.30449
7
N
S
2.8276
8 N
O
2.64549
9 N
N
3.10376
10 N
N
2.60476
11 C
NH2H2N
0.250538
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Compounds 4e11 were synthesized according to the re-
action sequence illustrated in Scheme 1. The structures of the
compounds were deduced by their 1H NMR, IR and mass
spectra, and their composition was determined through
elemental analyses. The chemical shift and multiplicity
patterns correlated well with the proposed structures, and
the elemental analysis showed good agreement between the
experimentally determined and the theoretically calculated
values.
The results of the biological screening and statistical
analysis (Table 1) showed that compounds 9
(IC50 ¼ 2.51  0.48 mM), 5 (IC50 ¼ 3.27  0.89 mM), and 7
(IC50 ¼ 4.57  0.64 mM) had high activity on the NCI (lung
cancer) cell line. Compound 9, which was the most potent
compound, exhibited comparable activity to the standard
drug methotrexate (IC50 ¼ 2.43  0.23 mM). Compound 11
had the lowest activity (IC50 ¼ 25.48  0.72). The order of
the activities of the target compounds on the NCI cell line
was the following: 9 < 5 < 7 < 8 < 10 < 6 < 4 < 11. The
screening analyses on MCF-7 cells (breast cancer cell line)
showed that compound 5 had the highest cytotoxic activity
and compound 11 had the lowest activity. The order of the
activities of the target compounds on theMCF-7 cell line was
5 < 9 < 7 < 8 < 10 < 4 < 6 < 11. The comparison of the
compounds (5, 7, 8 and 9) showed comparable activity to
methotrexate (IC50 ¼ 2.59  0.12 mM). The assay on the
HEK-293 normal cell line showed that compounds 9
(IC50 ¼ 6.81  0.61 mM), 5 (IC50 ¼ 5.82  0.61), and 7
(IC50¼ 13 0.95 mM) killed less normal cells compared with
methotrexate (IC50 ¼ 1.89  0.55 mM). The C log P data for
the tested compounds (Table 2) ranged from 3.10376 to
0.250538.
Discussion
Cancer is the leading cause of death in economically
developed countries and the second leading cause of death in
developing countries.14 The major challenges associated with
the currently available anticancer agents include theirTable 1: Cytotoxic activity of the tested compounds.
Compound
No.
Mean IC50
(mM)  SE
NCI MCF-7 HEK-293
4 16.91  0.74*** 14.97  0.57*** 12.31  0.42***
5 3.27  0.89 2.87  0.91 5.82  0.61***
6 12.32  0.73*** 16  0.54*** 14.82  0.22***
7 4.57  0.64 6.97  0.11*** 13  0.59***
8 6.14  0.81* 7.41  0.72*** 6.75  0.66***
9 2.51  0.48 3.42  0.48 6.81  0.61***
10 9.72  0.82*** 8.39  0.57*** 10.12  0.41***
11 25.48  0.72*** 31  0.41*** 46.34  0.23***
Methotrexate 2.43  0.23 2.59  0.12 1.89  0.55***
* indicates significant difference at P < 0.05 and *** indicates
significant difference at P < 0.001 compared with the reference
methotrexate, as determined using ANOVA and Tukey’s post-
test.selectivity and toxicity, resistance and the development of a
secondary malignancy.21 These drawbacks have motivated
the search for newer, more efficacious, and better-tolerated
antitumour drugs. Many techniques have been discovered
and described for the synthesis of anticancer drugs, which
include hybrid molecules and joined moieties. In a previous
study, we described the synthesis of some hybrid molecules
composed of a quinazolinone nucleus and amino acid de-
rivatives.15 These compounds were screened for their
anticancer activities, and the results revealed good activities
against different types of cell lines. In addition, these findings
encouraged us to modify the structure of these compounds as
a trial to produce more efficacious anticancer agents. The
newly synthesised compounds were designed by joining two
different moieties, namely quinazolinone and sulphonamide.
The structure of these derivatives can be divided into two
parts: the fixed part of the 6-fluoroquinazolinone moiety and
the changed part of the sulphonamide moiety at the third po-
sition of the quinazolinone ring. The optimisation of these
moleculeswasperformedat the third positionofquinazolinone
using different sulphonamide derivatives, namely, sulphanila-
mide in compound (4), sulphapyridine in compound (5), sul-
phafurazole in compound (6), sulphathiazole in compound (7),
sulphamethoxazole in compound (8), sulphamethazine in
compound (9), sulphamerazine in compound (10) and sul-
phaguanidine in compound (11). These compounds were
subjected to in vitro cytotoxic activity assays against two types
of cancer cell lines: NCI (lung cancer cell line) and MCF-7
(breast cancer cell line) cells to measure their anticancer ac-
tivity and one type of normal cell line HEK-293 (normal
epidermal kidney cell line) to measure their cytotoxic activity
M.F. Zayed et al.338on normal cells. The anticancer activity was assayed using the
MTT (3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyltetrazolium
bromide) assay. The IC50 values for the test and standard
compounds were calculated. In this study, compound 9 was
found to be significantly active against the NCI (lung cancer)
cell line, whereas compounds 5 and 7 were also significantly
active but less active than compound 9. The other compounds
exerted less activity on this cell line. Compound 5 was signifi-
cantly active against MCF-7 (breast cancer cell line) while
compounds 5 and 7 were also significantly active but less than
compound5. The other compounds exerted less activity on this
cell line. Compound 9 had the lowest cytotoxic activity on the
normal cell line (kidney HEK-293 cells), whereas the other
compoundshadhigher cytotoxic activity on this cell line.Based
on the findings of the present study, the authors concluded that
compound 9 is the most active compound with the lowest
cytotoxic activity on normal cells. This compound can be
subjected to further optimisation and in vivo studies to un-
derstand its action. The relationship between the lipophilicity
of the newly synthesised compounds and their biological ac-
tivity was measured through the correlation of anticancer ac-
tivity with the C log P values for all of the compounds. The
C log P value expresses the degree of lipophilicity of the
chemical compound. An increase in this value indicates an
increase in the lipophilic character of the tested compound.
This value was calculated using computerised models (Cam-
bridge software). It isworthwhile tonote that theC logPvalues
for compounds 9, 5, 7 and 8were higher than those of the other
four compounds, namely 10, 6, 4 and 11. These values may
explain the variation in their biological activity compared with
their lipophilicity. Interestingly, the C log P values for the
tested compounds agreedwith their potency levels. Compound
9, the most active compound, had the highest C log P value,
whereas compound 11, the least active compound, had the
lowest C log P value. Based on these results, we noted a cor-
relation between the anticancer activities of the target com-
pounds and their lipophilic characters.
Based on the results of this study, the strategy for the
synthesis of anticancer agents comprising the joining of
two pharmacophoric groups of sulphonamides and fluo-
rinated quinazolinone may be considered a promising way
to produce significantly active compounds; in addition,
increasing the lipophilicity of these compounds using
lipophilic substituents increases the anticancer activity of
the resulting compounds. Molecular optimisation, enzy-
matic assay and in vivo studies of compound 9 may be
considered a future plan for producing an effective anti-
cancer agent.Conclusions
Eight novel quinazolinoneesulphonamide derivatives
were synthesised and tested for their in vitro cytotoxic ac-
tivity. All of the newly synthesized compounds had signifi-
cant activity. Compound 9 showed promising activity and
was found to be safety because it was able to kill cancerous
cells more effectively than non-cancerous cells. Therefore,
this compound can be optimised and evaluated through
enzymatic assays and in vivo animal models for its future
development into a prototype molecule of a new class of
anticancer agents.Contributions
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